• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
185744 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
3 K& b0 q% X+ `- R: R
' X& G- F$ V2 i2 y
7 J9 _6 ]  L0 nSub-category:& Z& \+ x  G. T6 J8 L4 Z( X
Molecular Targets
6 G9 n; ?! o- I' h  f5 Z9 u7 C: V4 G3 Z6 B' ?- g
6 [0 L  J. l& Z( O! ?, }+ X/ ^- C9 Q
Category:
/ U* R& U: Y- ^- A0 a2 WTumor Biology
& x1 B9 T: M7 ]! \1 |1 f  A( V0 n7 g
2 ]+ v( u% A- t" u( S. Y: y
" u, k: @8 I2 yMeeting:
* p: e. v3 u" M2 G2011 ASCO Annual Meeting
7 w4 M+ E8 N3 X/ p" p- A+ Y
; [" h" P7 P( ?, G' O6 T& `/ e; J1 G1 x( l- q& L, R8 t3 x
Session Type and Session Title:; V7 r' f4 c! L4 m. U
Poster Discussion Session, Tumor Biology
  G! |# q$ o5 i3 [' q+ Z& }, c4 y+ I' |, u# v$ F  k

1 _" h' o3 ?9 c( h: xAbstract No:
+ E' Q; T% n7 ^# W10517 / q9 R3 l# g  U1 C& s
  N2 ~# h& L5 D
( c* ~, S) ?! c! _* N9 @2 n
Citation:
) e8 L5 n  H/ LJ Clin Oncol 29: 2011 (suppl; abstr 10517)
( F$ p3 e7 ?& t8 ^- A2 u4 R3 a+ A
# b, C  j/ w& j0 A, i8 Q2 y% }3 {$ _5 C2 x; Q  R5 b
Author(s):
/ O8 Q5 `% e/ `# ~4 oJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
8 l2 V, y. U4 d$ z9 v# g, m  {9 {' @: w; I* w' a

$ @5 ^2 C1 e' I, u1 I$ R$ M3 _# {
% }: m  ~  E8 a; p) B1 i. z; eAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
& S- Q0 A/ Q- X4 }! U, `# o3 m) J/ L8 Y7 ?2 i6 Y
Abstract Disclosures
: o9 v- a' {  @( J
3 K! m% I5 [" O  MAbstract:+ c0 M# ^$ r- c2 l
. b  V" j$ r' U, B
7 U# W" Z" e6 T6 I1 H3 u1 o
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
) g! t+ N) @3 B  g, x
1 y: F/ y  c- F. C( Q5 D2 E! s 6 K$ i$ ]* ^5 H7 Z: m+ {) ?/ `- e, x
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 0 Y' C% ]3 E6 E. `
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

* ~0 n6 V- C/ g7 f5 l0 A化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 . `) e' f( |' a/ o8 e$ y; p
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。; j5 o" p  f4 L/ o) c
ALK一个指标医院要900多 ...
! o) V) t9 q. A. S! e+ g
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
7 v* ]8 R/ d" c1 x: e% T
( ^) p8 _. k* R2 w) L' X. U现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表